2022
OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
Carpenter T, Cassinelli H, Glorieux F, Hetzer J, Merritt J, Moreira C, Portale A, Ward L, Woo C, Imel E. OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program. Journal Of The Endocrine Society 2022, 6: a191-a192. PMCID: PMC9624613, DOI: 10.1210/jendso/bvac150.395.Peer-Reviewed Original ResearchSerum alkaline phosphatase levelsNew safety concernsAlkaline phosphatase levelsLower limb deformitiesGroup 1Serum phosphorusGroup 2Group 3Burosumab therapyBone healthPhosphatase levelsHeight z-score changeLimb deformitiesHuman IgG1 monoclonal antibodyYear 1 visitRecombinant human IgG1 monoclonal antibodySerum phosphorus levelsZ-score changeYears of treatmentRadiographic Global ImpressionYear 1Safety concernsIgG1 monoclonal antibodyBone painDMP enrolment
2019
Micropulse Transscleral Cyclophotocoagulation A Look at Long-Term Effectiveness and Outcomes
Sarrafpour S, Saleh D, Ayoub S, Radcliffe NM. Micropulse Transscleral Cyclophotocoagulation A Look at Long-Term Effectiveness and Outcomes. Ophthalmology Glaucoma 2019, 2: 167-171. PMID: 32672586, DOI: 10.1016/j.ogla.2019.02.002.Peer-Reviewed Original ResearchConceptsYear 1 visitIntraocular pressureIOP reductionVisual acuityLong-term effectivenessMedication reductionMedication burdenMacular edemaAverage initial intraocular pressureOral carbonic anhydrase inhibitorsLight perceptionInitial intraocular pressureMedication burden reductionPersistent vision lossPercent of patientsPreoperative intraocular pressureRetrospective chart reviewMicropulse transscleral cyclophotocoagulationAverage intraocular pressureDose-response patternCount fingersNLP visionChart reviewInitial medicationMultivariable analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply